Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205315) titled 'A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Grit Biotechnology

Condition: Hematological Malignancy (Leukemia- Lymphoma)

Intervention: Biological: GT801 Injection

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: September 30, 2025

Target Sample Size: 28

Countries of Recruitm...